Replimune Group Inc
NASDAQ:REPL

Watchlist Manager
Replimune Group Inc Logo
Replimune Group Inc
NASDAQ:REPL
Watchlist
Price: 9.39 USD 1.29% Market Closed
Market Cap: 723.1m USD
REPL
/
Income Statement
/
Revenue

Replimune Group Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Replimune Group Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Replimune Group Inc
NASDAQ:REPL
Revenue
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$56.3B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.8B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
1%
Amgen Inc
NASDAQ:AMGN
Revenue
$33.4B
CAGR 3-Years
9%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$11B
CAGR 3-Years
13%
CAGR 5-Years
21%
CAGR 10-Years
34%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$14.2B
CAGR 3-Years
-4%
CAGR 5-Years
13%
CAGR 10-Years
18%

Replimune Group Inc
Glance View

Market Cap
723.1m USD
Industry
Biotechnology

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. The company is headquartered in Woburn, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2018-07-20. The firm is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The firm applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The firm is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1 (vusolimogene oderparepvec), RP2, and RP3. The firm is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.

REPL Intrinsic Value
Not Available
What is Intrinsic Value?

See Also

What is Replimune Group Inc's Revenue?
Revenue
0 USD

Based on the financial report for Dec 31, 2024, Replimune Group Inc's Revenue amounts to 0 USD.

Back to Top
ALPHA SPREAD
Follow us
Join more than 251,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.